ReviewNature reviews. Endocrinology2015
Novel RAAS agonists and antagonists: clinical applications and controversies.
Review in Nature reviews. Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 152 citations in OpenAlex.
- Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.Advances in therapy · 2020Trial
- Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide.Journal of structural biology: X · 2026Article
- From Multi-Species Screening to Targeted Investigation: Discovery of ACE Inhibitory Peptides inMolecules (Basel, Switzerland) · 2026Article
- Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.Cardiovascular & hematological disorders drug targets · 2026Review
- Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multidatabase Target Trial Emulation Studies.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Candesartan Mitigates Perioperative Neurocognitive Disorders by Modulating Hypertension-Linked Neuroinflammatory Factor.Neurochemical research · 2025Article
- A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.RSC medicinal chemistry · 2025Review
- Immune mediators in heart-lung communication.Pflugers Archiv : European journal of physiology · 2025Review
- Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.International journal of molecular sciences · 2024Review
- Combination therapy for kidney disease in people with diabetes mellitus.Nature reviews. Nephrology · 2024Review
- Exploring the potential effect of electroacupuncture on cardiovascular function and lipid profiles in spontaneously hypertensive rats.Integrative medicine research · 2024Article
- Gastrodin attenuates angiotensin II-induced vascular contraction and MLCK/p-MLCPharmaceutical biology · 2023Article
- Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation.Experimental & molecular medicine · 2023Article
- Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Association between antihypertensive medication and the risk of urinary tract infection (UTI) of outpatients: a retrospective cohort study.Infection · 2023Article
- Biomimetic Nanotechnology for SARS-CoV-2 Treatment.Viruses · 2023Review
- Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome.Frontiers in pharmacology · 2023Review
- Blood pressure and the kidney cortex transcriptome response to high-sodium diet challenge in female nonhuman primates.Physiological genomics · 2022Article
- Alamandine alleviated heart failure and fibrosis in myocardial infarction mice.Biology direct · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure homeostasis and vascular injury and repair responses. The RAAS was originally thought to be an endocrine system critically important in regulating blood pressure homeostasis. Yet, important local forms of the RAAS have been described in many tissues, which are mostly independent of the systemic RAAS. These systems have been associated with diverse physiological functions, but also with inflammation, fibrosis and target-organ damage. Pharmacological modulation of the RAAS has brought about important advances in preventing morbidity and mortality associated with cardiovascular disease. Yet, traditional RAAS blockers such as angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) only reduce the risk of disease progression in patients with established cardiovascular or renal disease by ∼20% compared with other therapies. As more components of the RAAS are described, other potential therapeutic targets emerge, which could provide improved cardiovascular and renal protection beyond that provided by an ACE inhibitor or ARB. This Review summarizes the present and future pharmacological manipulation of this important system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.